Aug 2026· Materials Today Bio· Vol 40, pp. 103540· 0 citations· 29 references
Medicine
TL;DR
MP-GCZ represents a promising comprehensive approach to overcoming TME-mediated resistance and may offer a valuable solution to enhance the clinical efficacy of cancer immunotherapy.
Abstract
Cancer immunotherapy has revolutionized the landscape of cancer treatment, particularly through the development of immune checkpoint blockade (ICB) targeting the PD-1/PD-L1 axis. However, the therapeutic efficacy of these interventions is frequently hindered by the immunosuppressive tumor microenvironment (TME), which is characterized by hypoxia, poor immune cell infiltration, and impaired antigen presentation. To overcome these barriers, MP-GCZ has been developed as a self-oxygenating biomimetic nanomotor to synergistically reprogram the TME and enhance antitumor immune responses through integrated multimodal mechanisms. This nanosystem combines photothermal therapy (PTT), cuproptosis-induced immunogenic cell death (ICD), and localized immune checkpoint modulation to address the complex immunosuppressive network of the TME. By leveraging a metal-organic framework scaffold, MP-GCZ enables controlled delivery of therapeutic components that alleviate hypoxia, trigger immunogenic tumor cell death, and enhance adaptive immune responses. When activated by near-infrared irradiation, MP-GCZ enhances dendritic cell maturation, increases infiltration of cytotoxic T lymphocytes, thereby transforming immunologically "cold" tumors into inflamed, immunogenic environments. Preclinical studies demonstrate that this strategy effectively suppresses both primary tumor growth and distant metastases, driven by systemic antitumor immunity. MP-GCZ represents a promising comprehensive approach to overcoming TME-mediated resistance and may offer a valuable solution to enhance the clinical efficacy of cancer immunotherapy.
A tumor-targeted nano-platform that co-delivers low-dose regorafenib with enzymatically versatile cerium oxide nanoparticles is engineered that could not only overcome the key limitations of conventional anti-angiogenic therapy but also provide a versatile and potent approach to sensitize osteosarcoma and other immunol...
Zili Lin, Qing Liu, Xiangyao Li et al.· Materials Today Bio· 0 citations
The potential of nanozymes to directly modulate immunometabolic pathways to empower immunotherapeutic efficacy is reviewed and the synergy of nanozymes with established immunotherapeutics such as immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines is explored.
Bi-Li Zhang, Meng-Huan Li, Yan Hu et al.· Small· 0 citations
By facilitating the crucial transition from “cold” to “hot” tumors, nanotechnology offers promising potential to amplify antitumor immunity and may contribute to improving clinical outcomes in esophageal cancer.
Qiaoyi Shen, Yi-Bo Gao· Frontiers in Immunology· 0 citations
Future efforts should prioritize structurally simplified, mechanistically defined, tumor-microenvironment-responsive platforms, together with biomarker-guided patient stratification and standardized evaluation systems, to facilitate the translation of RCC nano-immunotherapy into reproducible treatment strategies with c...
Man Luo, Peng Tang, Xi-Chan Chen et al.· International Journal of Nan...· 0 citations
This new strategy, where oxygen-modifying nanoparticles can be combined with immunotherapy, marks a new future for HCC management and reduces hypoxia and enhances immune response.
Chunzhong Qiao, T. Cheng, Jun-Sheng Li· Methods· 0 citations
A multifunctional manganese-based nanozyme loaded with indocyanine green (ICG) is developed to reprogram the immunosuppressive TME for potentiated phototherapy combined with immunotherapy and elicits robust immune memory to prevent recurrence and metastasis.
Chen-Lu Huang, Han-Yong Wang, Xin-Yu Yang et al.· ACS Nano· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.